Breast cancer research should focus on subtypes with worse prognosis, such as triple negative prognosis.

Compilation
Breast cancer continues to be a major concern for the medical and scientific community. In Spain, It is expected that 36,395 new cases will be diagnosed in 2024. which emphasizes the relevance of continuing research into this disease. Despite progress, breast cancer remains the leading cause of death in women aged 35 to 55 years. Although 80% of patients survive five years after diagnosis, the reality is that there are more aggressive types of breast cancer that pose more serious problems such as triple negative subtype and those cases where metastases develop.

Oncology experts warn that it is critical to expand our knowledge of these subtypes because triple-negative breast cancer, which affects a small percentage of patients, is resistant to many currently available treatments. In addition, the development of metastases remains a major concern as it is estimated that Approximately 30% of women diagnosed with early stage disease experience recurrence with distant metastases.. This highlights the importance of finding more effective treatments that can prevent disease progression and improve patients’ quality of life.

About 30% of women diagnosed at an early stage of the disease suffer recurrence with distant metastases.

For women with hormone-positive, HER2-negative breast cancer, who make up about 70% of patients, 15% face a high risk of recurrence, and of these, 25% will recur in the first five years. For the HER2-positive subtype, which affects 15% to 20% of all patients, the risk of relapse after five years ranges from 15% to 20%, despite targeted treatment.

Given these numbers, the need continue research into the molecular mechanisms underlying disease relapse and how they can be dealt with more effectively.

He Dr. Miguel Martin, President of Geicam, emphasizes that advances in research have played a key role in the development of more specific and less toxic treatments that have allowed patients to live longer. However, he cautions that much remains to be done, especially in cases of metastatic cancer, where The goal is to make the disease chronic and ensure patients have an optimal quality of life.. “Advances in research allow us to develop more specific, effective and less toxic treatments. In the case of metastasis, our goal is to transform the disease into a chronic form, that is, to ensure long-term survival of patients and maintain quality of life,” he said. indicates.

Women who lead a sedentary lifestyle are 71% more likely to develop breast cancer

To raise awareness and funds, Geicam launched a campaign #IDoyHardForHers, which emphasizes the role of physical exercise both in the prevention of breast cancer and in the oncological process. Studies such as EpiGeicam have shown that women who lead a sedentary lifestyle are 71% more likely to develop breast cancer, which highlights the importance of maintaining an active life. In addition, the campaign seeks to demonstrate the positive impact of research in improving the treatment and care of patients diagnosed with this disease.

The campaign has the support of community leaders and journalists, who use videos and social media content to explain the benefits of exercise and its link to reducing the risk of breast cancer. They are also inviting the public to make a donation. “minutes” for research is a symbolic gesture that translates into financial support aimed at improving knowledge about the disease and saving lives.

Additionally, to help spread awareness of the importance of breast cancer research, Geicam has created Geicam Journalism Award for Innovation in Breast Cancer, What are you looking for recognize the work of the media in disseminating quality information about this disease and the scientific advances achieved. This award, endorsed by the National Association of Medical Informants (ANIS), will be presented in 2025 during the Geicam International Symposium in Madrid. Recognition will include two categories: print media and audiovisual materials, with a financial award of €2,000 each.